Zidovudine resistance mutations and human immunodeficiency virus type 1 DNA burden: Longitudinal evaluation of six patients under treatment

Infection

Volumn 24, Issue 6, 1996, Pages 419-425

  Zazzi, M ^a   Catucci, M ^a   De Milito, A ^a   Romano, L ^a   Venturi, G ^a   Almi, P ^b   Gonnelli, A ^b   Rubino, M ^b   Valensin, P E ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; VIRUS DNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; LONGITUDINAL STUDY; LYMPHOCYTE COUNT; MONITORING; MONONUCLEAR CELL; PATHOGENESIS; POLYMERASE CHAIN REACTION; VIRUS GENE;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; DRUG MONITORING; DRUG RESISTANCE; GENES, POL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MOLECULAR SEQUENCE DATA; MUTATION; POLYMERASE CHAIN REACTION; VIRAL LOAD; ZIDOVUDINE;

EID: 0030451263     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01713041     Document Type: Article

References (46)

1. De Clercq, E.: Antiviral therapy for human immunodeficiency virus infections. Clin. Microbiol. Rev. 8 (1995) 200-239.
2. Mitsuya, H., Weinhold, K. J., Furman, P. A., St. Clair, M., Nusinoff Lehrman, S., Gallo, R. C., Bolognesi, D., Barry, D. W., Broder, S.: 3'-azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivily and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. USA 82 (1985) 7096-7100.
3. Larder, B. A., Darby, G., Richman, D. D.: HIV with reduced sensitivity to zidovudine isolated during prolonged therapy. Science 243 (1989) 1731-1734.
4. Rooke, R., Tremblay, M., Soudeyns, H., De Stephano, L., Yao, X.-J., Fanning, M., Montaner, J. S. G., O'Shaughnessy, M., Gelmon, K., Tsoukas, C., Gill, J., Ruedy, J., Wainberg, M. A., Canadian Zidovudine Multi-centre Study Group: Isolation of drug-resistant variants of HIV-1 from patients on long-term zidovudine therapy. AIDS 2 (1989) 411-415.
5. Land, S., Treolar, G., McPhee, D.: Decreased in vitro susceptibility to zidovudine of HIV isolates obtained from patients with AIDS. J. Infect. Dis. 161 (1990) 326-329.
6. Boucher C. A. B., Tersmette, M., Lange, J. M. A., Kellam, P., de Gorde, R. E. Y., Mulder, J. W., Darby, G., Goudsmit, J., Larder, B. A.: Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 336 (1990) 585-590.
7. Land, S., McGavin, C., Lucas, R., Birch, C.: Incidence of zidovudine-resistant human immunodeficiency virus isolated from patients before, during, and after therapy. J. Infect. Dis. 166 (1992) 1139-1142.
8. Larder, B. A., Kemp, S. D.: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246 (1989) 1155-1158.
9. Larder, B. A., Coates, K. E., Kemp, S. D.: Zidovudine-resistant human immunodeficiency virus selected by passage in cell culture. J. Virol. 65 (1991) 5232-5236.
10. Kellam, P., Boucher, C. A. B., Larder, B. A.: Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc. Natl. Acad. Sci. USA 89 (1992) 1934-1938.
11. Schinazi, R. F., Lloyd, R. M., Ramanathan, C. S., Taylor, E. W.: Antiviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions. Antimicrob. Agents Chemother. 38 (1994) 268-274.
12. Boucher, C. A. B., van Leeuwen, R., Kellam, P., Schipper, P., Tijnagel, J., Lange, J. M. A., Larder, B. A.: Effects of discontinuation of zidovudine treatment on zidovudine sensitivity of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 37 (1993) 1525-1530.
13. Eron, J. J., Chow, Y.-K., Caliendo, A. M., Videler, J., Devore, K. M., Cooley, T. P., Liebman, H. A., Kaplan, J. C., Hirsch, M. S., D'Aquila, R. T.: pol mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimicrob. Agents Chemother. 37 (1993) 1480-1487.
14. Montaner, J. S. G., Singer, J., Schechter, M. T., Raboud, J. M., Tsoukas, C., O'Shaughnessy, M., Ruedy, J., Nagai, K., Salomon, H., Spira, B., Wainberg, M. A.: Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the Multicentre Canadian AZT Trial. AIDS 7 (1993) 7189-7196.
15. Kuritzkes, D. R., Bell, S., Bakhtiari, M.: Rapid CD4+ cell decline after sexual transmission of a zidovudine-resistant syncytium-inducing isolate of HIV-1. AIDS 8 (1994) 1017-1019.
16. Larder, B. A., Kellam, P., Kemp, S. D.: Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5 (1991) 137-144.
17. St. Clair, M. H., Martin, J. L., Tudor-Williams, G., Bach, M. C., Vavko, C. L., Kino, D. M., Kellam, P., Kemp, S. D., Larder, B. A.: Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 253 (1991) 1557-1559.
18. Larder, B. A.: 3'-azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. 36 (1992) 2664-2669.
19. Larder, B. A., Kellam, P., Kemp, S. D.: Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro. Nature 365 (1993) 451-453.
20. Kellam, P., Boucher, C. A. B., Tijnagel, J. M. G. H., Larder, B. A.: Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose genotypes confer increasing levels of drug resistance. J. Gen. Virol. 75 (1994) 341-351.
21. Larder, B. A.: Interactions between drug resistance mutations human immunodeficiency virus type 1 reverse transcriptase. J. Gen. Virol. 75 (1994) 951-957.
22. Richman, D. D.: Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37 (1993) 1207-1213.
23. Centers for Disease Control and Prevention: 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Morbid. Mortal. Weekly Rep. 41 (1992) 1-18.
24. Piatak, M., Luk, K.-C., Williams, B., Lifson, J. D.: Quantitative competitive polymerase chain reaction for accurate quantitation of HIV DNA and RNA species. Biotechniques 14 (1993) 70-79.
25. Hart, C., Chang, S. Y., Kwok, S., Sninsky, J. J., Ou, C.-Y., Schochetman, C.: A replication-deficient HIV-1 DNA used for quantification of the polymerase chain reaction (PCR). Nucleic Acids Res. 18 (1990) 4029-4030.
26. Sykes, P. J., Neoh, S. H., Brisco, M. J., Hughes, E., Condon, J., Morley, A. A.: Quantitation of targets for PCR by use of limiting dilution. Biotechniques 13 (1992) 444-449.
27. Zazzi, M., Romano, L., Brasini, A., Valensin, P. E.: Nested polymerase chain reaction for detection of human immunodeficiency virus type 1 DNA in clinical specimens. J. Med. Virol. 38 (1992) 172-174.
28. Fitzgibbon, J. E., Howell, R. M., Schwartzer, T. A., Gocke, D. J., Dubin, D. T.: In vivo prevalence of azidothymidine (AZT) resistance mutations in an AIDS patient before and after AZT therapy. AIDS Res. Hum. Retroviruses 7 (1991) 265-269.
29. Boucher, C. A. B., O'Sullivan, E., Mulder, J. W., Ramautarsing, C., Kellam, P., Darby, G., Lange, J. M. A., Goudsmit, J., Larder, B. A.: Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J. Infect. Dis. 165 (1992) 105-110.
30. Tudor-Williams, G., St. Clair, M. H., Mc Kinney, R. E., Maha, M., Walter, E., Santacroce, S., Mintz, M., O'Donnell, K., Rudoll, T., Vavko, C. L., Connor, E. M., Wilfert, C. M.: HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet 339 (1992) 15-19.
31. Kozal, M. J., Shafer, R. W., Winters, M. A., Katzenstein, D. A., Merigan, T. C.: A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J. Infect. Dis. 167 (1993) 526-532.
32. Kellam, P., Larder, B. A.: Retroviral recombination can lead to linkage of reverse transcriptase mutations that confer increased zidovudine resistance. J. Virol. 69 (1995) 669-674.
33. Frenkel, L. M., Wagner II, L. E., Atwood, S. M., Cummins, T. J., Dewhurst, S.: Specific, sensitive, and rapid assay for human immunodeficiency virus type 1 pol mutations associated with resistance to zidovudine and didanosine. J. Clin. Microbiol. 33 (1995) 342-347.
34. Erice, A., Mayers, D. L., Strike, D. G., Sannerud, K. J., McCutchan, F. E., Henry, K., Balfour, H. H.: Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N. Engl. J. Med. 328 (1993) 1163-1165.
35. Mohri, H., Singh, M. K., Ching, W. T. W., Ho, D. D.: Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients. Proc. Natl. Acad. Sci. USA 90 (1993) 25-29.
36. Najera, I., Holguin, A., Quinones-Mateu, M. E., Munoz-Fernandez, M. A., Najera, R., Lopez-Galindez, C., Domingo, E.: pot gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69 (1995) 23-31.
37. Albert, J., Wahlberg, J., Lundeberg, J., Cox, S., Sandstrom, E., Wabren, B., Uhlen, M.: Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in posttreatment sera. J. Virol. 66 (1992) 5627-5630.
38. Gao, Q., Gu, Z., Parniak, M. A., Li, X., Wainberg, M. A.: In vitro selection of human immunodeficiency virus type 1 resistant to 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine. J. Virol. 66 (1992) 12-19.
39. Muckenthaler, M., Gunkel, N, Levantis, P., Broadhurst, K., Goh, B., Colvin, B., Forster, G., Jackson, G. G., Oxford, J. S.: Sequence analysis of an HIV-1 isolate which displays unusually high-level AZT resistance in vitro. J. Med. Virol. 36 (1992) 79-83.
40. Sheeby, N., Desselberger, U.: Sequence analysis of reverse transcriptase genes of ZDV (AZT)-resistant and -sensitive human immunodeficiency virus type 1 strains. J. Gen. Virol. 74 (1993) 223-228.
41. Holodniy, M., Mole, L., Margolis, D., Moss, J., Dong, H., Boyer, E., Urdea, M., Kolberg, J., Eastman, S.: Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. J. Virol. 69 (1995) 3510-3516.
42. Bagnarelli, P., Menzo, S., Valenza, A., Paolucci, S., Petroni, S., Scalise, G., Sampaolesi, R., Manzin, A., Varaldo, P. E., Clementi, M.: Quantitative molecular monitoring of human immunodeficiency virus type 1 activity during therapy with specific antiretroviral compounds. J. Clin. Microbiol. 33 (1995) 16-23.
43. Michael, N. L., Vahey, M., Burke, D. S., Redfield, R. R.: Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infections in humans: evidence for viral replication in all stages of HIV disease. J. Virol. 66 (1992) 310-16.
44. Gupta, P., Kingsley, L., Armstrong, J., Ding, M., Cottrill, M., Rinaldo, C.: Enhanced expression of human immunodeficiency virus type 1 correlates with development of AIDS. Virology 196 (1993) 586-595.
45. Mellors, J. D., Rinaldo, C. R., Gupta, P., White, R. M., Todd, J. A., Kingsley, L. A.: Prognosis in HIV infection predicted by the quantity of virus in plasma. Science 272 (1996) 1167-1170.
46. Merigan, T. C., Hirsch, R. L., Fisher, A. C., Meyerson, L. A., Goldstein, G., Winters,. M. A.: The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin. AIDS 10 (1996) 159-165.